A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C—C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis (LF). A randomized, double‐blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Hepatology
Prif Awduron: Friedman, Scott L., Ratziu, Vlad, Harrison, Stephen A., Abdelmalek, Manal F., Aithal, Guruprasad P., Caballeria, Juan, Francque, Sven, Farrell, Geoffrey, Kowdley, Kris V., Craxi, Antonio, Simon, Krzysztof, Fischer, Laurent, Melchor‐Khan, Liza, Vest, Jeffrey, Wiens, Brian L., Vig, Pamela, Seyedkazemi, Star, Goodman, Zachary, Wong, Vincent Wai‐Sun, Loomba, Rohit, Tacke, Frank, Sanyal, Arun, Lefebvre, Eric
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2018
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947654/
https://ncbi.nlm.nih.gov/pubmed/28833331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.29477
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg